July 2022

活動性乾癬性関節炎患者においてguselkumab は複合 指標の各ドメインおよび全般的な有効性を示す

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac375

This analysis found that patients with active PsA who receive treatment with guselkumab can achieve robust and sustained low disease activity or remission. In reaching this conclusion investigators sought to evaluate the efficacy of guselkumab for the treatment of active PsA through the use of composite indices.

Keywords:

February 2022

関節リウマチ患者さんにおけるJAK阻害薬の高比重 および低比重リポタンパクへの影響: システマティックレ ビューとネットワークメタ解析

Clin Rheumatol. 2022. Epub ahead of print doi: 10.1007/s10067-021-06003-z

Systematic review and network meta-analysis highlight that RA patients who receive recommended doses of the five approved JAK inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib, and peficitinib) are likely to experience an increase in serum low- and high-density lipoprotein (LDL and HDL) levels.JAK inhibitors have been associated with alterations in levels of LDL and HDL cholesterol, which may lead to dyslipidaemia (an important risk factor for cardiovascular disease). However, the e...

Keywords: